

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: :  
BRUCE A. HAY, ET AL. :  
APPLICATION NO.: NOT YET ASSIGNED : Examiner: David Lukton  
(anticipated)  
FILING DATE: HEREWITH : Group Art Unit: 1653  
(anticipated)  
TITLE: SOMATOSTATIN ANTAGONISTS and :  
AGONISTS THAT ACT AT THE SST :  
SUBTYPE 2 RECEPTOR :

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445. A prompt and favorable response is earnestly solicited.

Respectfully submitted,



E. Victor Donahue  
Attorney for Applicant(s)  
Reg. No. 35,492

Date: September 8, 2003

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733-2739

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				ATTY. DOCKET NO. PC11862B				SERIAL NO. Not Assigned					
				APPLICANT Bruce Hay, et al.									
				FILING DATE September 8, 2003				GROUP Not Assigned					
<b>U.S. PATENT DOCUMENTS</b>													
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
US	5	9	3	6	0	8	9	8/10/99	Carpino, et al.				
<b>FOREIGN PATENT DOCUMENTS</b>													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES NO	
WO	9	9	6	4	4	0	1	12/16/99	PCT/US				
WO	9	8	4	4	9	2	2	10/15/98	PCT/US				
WO	9	8	4	5	2	8	5	10/15/98	PCT/US				
WO	9	8	4	4	9	2	1	10/15/98	PCT/US				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Sadaf Farooqu et al., "The Therapeutic Value of Somastatin and Its Analogues" <i>Pituitary</i> Vol. 2, pp. 79-88 (1999)											
		Yogesh C. Patel, et al., "Somatostatin Receptors", <i>TEM</i> , Vol. 8, No. 10, (1997) pages 398-404											
		Simon J. Hocart, et al., "Potent Antagonists of Somatostatin: Synthesis and Biology"; <i>J. Med. Chem.</i> Vol. 41, pp. 1146-1154											
		Susan P. Rohrer, et al., "Rapid Identification of Subtype-Selective Agonists of the Somatostatin Receptor Through Combinatorial Chemistry" <i>Science</i> Vol. 282, pp. 737-740; (1998)											
		Henning Grønbaek, et al. "Potential Role of Octreotide in the Treatment of Diabetes" <i>Prog Basic Clin Pharmacol. Basel</i> , vol. 10, pp. 103-128; (1996)											
		Vicente Martinez, et al., "High Basal Gastric Acid Secretions in Somatostatin Receptor Subtype 2 Knockout Mice"; <i>American Gastroenterology</i> (1998) 114 pp. 1125-1132											
		Lihu Yang, et al., "Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2"; <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 10836-10841, (1998)											
		Muhammad Zaki, et al., "Somatostatin Receptor Subtype 2 Mediates Inhibition of Gastrin and Histamine Secretion from Human, Dog and Rat Antrum"; <i>Gastroenterology</i> Vol. 111, pp. 919-924 (1996)											
		William R. Baumbach, et al., "A Linear Hexapeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats" <i>Molecular Pharmacology</i> , Vol. 54, pp.864-873 (1998)											
		Torsello, Antonio, ( <i>Endocrinology</i> 143 (5) 1968, 2002)											
		McFadyen, "Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH <sub>2</sub> (Et): effects on opioid receptor binding and activation" <i>Journal of Peptide Research</i> (2000 Mar) 55 (3) 255-61)											
		Keith, "mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain" <i>Molecular Pharmacology</i> 53 (3) 377-84, 1998											
		Xiao, "Relationship between cAMP production in cells and in vivo activity" <i>Biochemistry</i> 40, 2860, 2001											
		Lunec, "MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma" <i>Melanoma Research</i> (May 1992) 2 (1) 5-12											
EXAMINER				. DATE CONSIDERED									
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>													

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE